The endocytosis-linked protein dynamin associates with caveolin-1 and is tyrosine phosphorylated in response to the activation of a noninternalizing epidermal growth factor receptor mutant.
Several studies have shown that an EGF receptor C-terminal truncation at residue 973 (CT973) attenuates ligand-induced receptor endocytosis and is associated with cell transformation. Previously, we have shown that EGF stimulation of murine B82L fibroblasts expressing CT973 EGF receptors can promote the tyrosine phosphorylation of caveolin-1, which is a major component of caveolae membranes. Because dynamin plays an essential role in receptor-mediated endocytosis via clathrin-coated pits and caveolae, and because dynamin has been localized to caveolae, we tested the hypothesis that dynamin associates with caveolin-1 and is differentially modified in response to the abnormal actions of internalization-defective EGF receptors. We found that dynamin coimmunoprecipitates with caveolin-1 in cells containing normal or CT973 EGF receptors, but EGF stimulated the tyrosine phosphorylation of dynamin only in cells expressing truncated/oncogenic EGF receptors. Maximum dynamin phosphorylation was observed within 15 min of EGF administration and decreased thereafter. Furthermore, phosphotyrosine-containing proteins in the dynamin immunocomplexes were observed to be reactive with anticaveolin-1 antibodies. The EGF receptor does not appear to directly phosphorylate dynamin because a Src antagonist, PP1, inhibited the EGF-induced tyrosine phosphorylation of dynamin at a concentration that does not block EGF receptor autophosphorylation. These results provide the first evidence that caveolin-1 and dynamin form a complex, and that the EGF-induced tyrosine phosphorylation of dynamin occurs via a Src inhibitor-sensitive signaling pathway that is associated with the aberrant actions induced by internalization-defective EGF receptors.
Kim
Yong-Nyun
YN
Department of Biomolecular Chemistry, University of Wisconsin, 1300 University Avenue, Madison, WI 53706-1532, USA.
Bertics
Paul J
PJ
D000818:Animals; D051242:Caveolin 1; D022461:Caveolins / Q000502:physiology*; D002460:Cell Line; D034281:Dynamins; D004705:Endocytosis / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066246:ErbB Receptors / Q000235:genetics* / Q000502:physiology*; D005347:Fibroblasts / Q000378:metabolism; D020558:GTP Phosphohydrolases / Q000502:physiology*; D006801:Humans; D051379:Mice; D009154:Mutation / Q000235:genetics / Q000502:physiology; D010766:Phosphorylation; D011233:Precipitin Tests; D014443:Tyrosine / Q000378:metabolism / Q000502:physiology*; D019061:src-Family Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
C495540:CAV1 protein, human; C495541:Cav1 protein, mouse; D051242:Caveolin 1; D022461:Caveolins; D004791:Enzyme Inhibitors; D014443:Tyrosine; D066246:ErbB Receptors; D019061:src-Family Kinases; D020558:GTP Phosphohydrolases; D034281:Dynamins